Adverse event management and pharmacovigilance for UK telehealth operators

Adverse event management in UK telehealth is one of the most regulated and least discussed operational functions. Every operator dispenses medicines under MHRA oversight. Every operator is implicitly part of the UK pharmacovigilance system. Most operators have a vague understanding of Yellow Card reporting and a precise understanding of the consequences of getting it wrong. This piece is the operational guide for compliance and clinical operations leaders.

What pharmacovigilance actually means for telehealth operators

Pharmacovigilance is the science and activities relating to the detection, assessment, understanding, and prevention of adverse effects from medicines. For UK telehealth operators, it means a structured system for capturing, evaluating, and reporting suspected adverse drug reactions. Every operator dispensing medicines participates in this system — the only question is how systematically. Pharmacovigilance is regulated under MHRA in the UK and applies regardless of operator size.

The MHRA Yellow Card scheme — what triggers a report

The Yellow Card scheme is the UK system for reporting suspected adverse drug reactions to MHRA. Reportable events include: any suspected adverse reaction to a black-triangle medicine, serious suspected reactions to any medicine, suspected reactions in children, and suspected adverse reactions in elderly patients. The threshold for reporting is suspicion, not proof. Withhold a report at your operational peril — MHRA enforcement around under-reporting has tightened across 2024-2026.

Capturing adverse events at source — patient, prescriber, pharmacy

Adverse events surface from three sources. Patients reporting symptoms post-dispense, usually via support. Prescribers identifying patterns during consultations or follow-ups. Pharmacy teams noticing repeated returns or dosing concerns. A working pharmacovigilance system captures all three inputs and routes them to the responsible clinician for assessment within defined SLAs. Single-source pharmacovigilance — relying only on patient reports — misses the patterns clinicians see first.

The internal review process — clinician sign-off and documentation

Every captured event needs clinical assessment. The responsible prescriber reviews the report, determines causality and seriousness, decides whether the patient needs clinical intervention, and documents the decision. The documentation becomes part of the patient record and the operator's audit trail. MHRA can request this documentation; brands that do not have it discover that fact at the worst time. Documentation discipline is the foundation.

Reporting timelines and SLAs

Serious suspected adverse drug reactions should be reported to MHRA as soon as possible. Non-serious reactions in routine clinical practice have a longer window but should not be deferred indefinitely. A workable internal SLA: clinical assessment within 24-48 hours of capture, Yellow Card submission within seven days for non-serious events, and immediate submission for serious events. The clock starts when the report is captured, not when it is investigated.

Building a pharmacovigilance function that scales

At low volume, pharmacovigilance lives with the superintendent pharmacist or clinical lead as a part-time responsibility. At scale, it becomes a dedicated function with named accountability and weekly review cadence. The transition happens around the same time as other clinical operations transitions — typically at 5,000+ active patients depending on category. Brands operating in higher-risk categories (controlled drugs, weight management, off-label use) need to scale pharmacovigilance earlier. PExpo's clinical operations include a structured pharmacovigilance workflow so operators do not need to build it from scratch.

Pharmacovigilance is the function that protects the operator as much as the patient. Treat it as both.

Adverse event management is the function most likely to be invisible until it fails. The operators who build it properly — clear capture rules, defined clinical sign-off, documented audit trail, scaled pharmacovigilance team — protect their patients and their licence to operate. The ones who treat it as a once-a-year compliance exercise put both at risk. Our clinic model page describes the operational scope that includes adverse event handling, and our brand model page covers the equivalent on the white-label side.